Illumina (NASDAQ:ILMN) Issues FY25 Earnings Guidance

Illumina (NASDAQ:ILMN) updated its FY25 earnings guidance on Monday. The company provided EPS guidance of $4.50 for the period, compared to the consensus EPS estimate of $4.51.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ILMN shares. Stephens increased their target price on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Hsbc Global Res cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. Royal Bank of Canada lowered their target price on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Robert W. Baird cut their price target on Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, March 5th. Finally, TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and lowered their price objective for the company from $177.00 to $140.00 in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Illumina currently has an average rating of “Moderate Buy” and an average target price of $149.25.

Illumina Trading Down 0.8 %

Illumina stock traded down $0.65 during midday trading on Monday, reaching $85.97. The stock had a trading volume of 2,960,847 shares, compared to its average volume of 2,655,172. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The firm has a market cap of $13.62 billion, a price-to-earnings ratio of -11.19, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. Illumina has a 52-week low of $80.18 and a 52-week high of $156.66. The company has a fifty day moving average of $118.38 and a 200 day moving average of $131.48.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, analysts anticipate that Illumina will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.